12th International HBV Cure Workshop
In-Person Event
Nov 05, 2025
Washington, Dist of Col, USA
OVERVIEW
12th International HBV Cure Workshop is organized by MCI Canada and will be held on Nov 05, 2025 at Marriott Marquis Washington, Washington, Dist of Col, United States of America.
Description:
This workshop also brings together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.
Since its inception in 2014, the International HBV Cure Workshop has been a pivotal scientific platform aimed at accelerating the progress towards finding a cure for HBV. With over 250 million people worldwide living with hepatitis B, the workshop's goal is to update participants on the latest advancements in HBV cure research. The event will be highly interactive, featuring contributions from experts in basic, translational, and clinical HBV research.
The HBV treatment landscape is experiencing significant transformations and is on the brink of a paradigm shift. The emergence of numerous new treatment options brings great hope for reducing the disease burden, simplifying treatment protocols, and potentially curing and eradicating HBV infection. To optimize curative treatments for HBV, distinguished speakers from around the world will present the latest therapeutic options for viral hepatitis. Experts will discuss the path forward to curing this deadly disease, which can lead to liver cirrhosis and liver cancer. Extensive discussions will cover the appropriate endpoints for therapeutic trials and the combination of different agents targeting the virus and/or immune system. This workshop also serves as a platform for global interdisciplinary experts to provide a framework for collaboration between academia and industry, with the ultimate goal of curing hepatitis B.
Preliminary Program:
| Wednesday, November 5, 2025 | ||
| WORKSHOP OPENING | 8:30 AM - 8:40 AM | |
| SESSION I | 8:40 AM - 10:10 AM | • 08:40 a.m. - 09:00 a.m. New guidelines and re-thinking HBV nomenclature for therapeutic endpoints • 09:00 a.m. - 09:20 a.m. Will long acting NA's help our goals to achieve HBV cure or not? • 09:20 a.m. - 09:40 a.m. Real-world HBsAg levels and the impact HBsAg cut-offs for clinical trial enrollment • 09:40 a.m. - 10:10 a.m. Discussion |
| AM BREAK | 10:10 AM - 10:30 AM | |
| SESSION II | 10:30 AM - 12:00 PM | • 10:30 a.m. - 10:50 a.m. Gene and Epigenome editing: what is the current knowledge on efficacy and risks? • 10:50 a.m. - 11:10 a.m. Advances in HDV treatment: Bulevirtide vs. mAb vs. small molecule, is there a front runner? • 11:10 a.m. - 11:30 a.m. Immune dysfunction vs. exhaustion - splitting hairs or real impact on immunotherapy • 11:30 a.m. - 12:00 p.m. Discussion |
| LUNCH BREAK | 12:00 PM - 1:00 PM | |
| SESSION III | 1:00 PM - 2:40 PM | • 1:00 p.m. - 1:20 p.m. Translational immunology in oncology: a successful paradigm for cure studies? • 1:20 p.m. - 1:30 p.m. Efficacy of therapeutic vaccination with a novel checkpoint modifier. • 1:30 p.m. - 1:40 p.m. Leveraging prior vaccination to enhance functional cure rates in siRNA/IFN-? combination studies • 1:40 p.m. - 1:50 p.m. ImmTAV®: Soluble, bi-specific T cell receptors to target HBsAg-positive hepatocytes • 1:50 p.m. - 2:00 p.m. Anti-HBs combination therapies for treatment in HBV/HDV patients • 2:00 p.m. - 2:40 p.m. Discussion |
| PM BREAK | 2:40 PM - 3:10 PM | |
| SESSION IV | 3:10 PM - 4:55 PM | • 3:10 p.m. - 3:30 p.m. Universal Standards for new HBV biomarkers to improve their utility. • 3:30 p.m. - 3:40 p.m. Evidence for durable HBsAg declines after long-term CAM therapies. • 3:40 p.m. - 3:50 p.m. RNA interference with ASO: Is functional cure sustained long-term? • 3:50 p.m. - 4:00 p.m. RNA interference with ASO: Latest results from new kid on the block. • 4:00 p.m. - 4:10 p.m. Bulevirtide + IFN-? in long-term treated HDV patients: optimal duration for sustained responses. • 4:10 p.m. - 4:25 p.m. Gene and epigenomic editing: early results in 3 elevator pitches. • 4:25 p.m. - 4:55 p.m. Discussion |
| CLOSING REMARKS | 4:55 PM - 5:00 PM | |
| NETWORKING RECEPTION | 5:00 PM - 7:00 PM | |
KEY DATES
05 Nov, 2025
Event Start Date
05 Nov, 2025
Event End Date
TARGET AUDIENCE
PhysicianGastroenterologistsInfectious Diseases PhysicianSPECIALITIES
GastroenterologyInfectious DiseaseCONFERENCE SUMMARY
The 12th International HBV Cure Workshop is set to advance the field of hepatitis B research in 2025. This prestigious conference will bring together leading experts to discuss innovative therapies and potential cures for HBV. Attendees can expect insightful presentations, engaging panel discussions, and valuable networking opportunities. Researchers, clinicians, and industry professionals will delve into the latest findings and share best practices in HBV treatment. Don't miss this chance to be part of a transformative event shaping the future of hepatitis B care. Secure your spot now for this pivotal workshop!
SUGGESTED HOTELS
CONFERENCE VENUE
Marriott Marquis Washington,CANCELLATION & REFUND POLICY
Registration Modification and Cancellation:
For cancellations received prior to Tuesday, September 30, 2025, midnight EST, deposits will be refunded minus a 25% administrative charge. After this date, no refunds will be possible.
A name change will be considered as a modification and will be charged 25 USD.
A handling fee of 25 USD per registration will be charged for every registration modification received, including a name change.
RELATED CONFERENCES & LIVE WEBINARS
Quick Links